Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 111 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from respiratory illnesses. The firm's research is engaged in the areas of inflammation and immunology. Its Nezulcitinib (TD-0903) product is a lung-selective pan Janus-associated kinase inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019. The firm is also developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Velusetrag (TD-5108), Selective 5-HT4 Agonist (TD-8954).